Coherus Oncology
CHRS
187 hedge funds and large institutions have $1.22B invested in Coherus Oncology in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 54 increasing their positions, 78 reducing their positions, and 21 closing their positions.
14% more capital invested
Capital invested by funds: $1.08B → $1.22B (+$147M)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
1% less funds holding
Funds holding: 188 → 187 (-1)
3.31% less ownership
Funds ownership: 102.84% → 99.53% (-3.3%)
21% less call options, than puts
Call options by funds: $1.83M | Put options by funds: $2.32M
31% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 78
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$15.8M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$7.17M |
| 3 |
FAM
Fred Alger Management
New York
|
+$6.34M |
| 4 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$3.72M |
| 5 |
Millennium Management
New York
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$15.3M |
| 2 |
BlackRock
New York
|
-$6.31M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.01M |
| 4 |
SCM
Sio Capital Management
New York
|
-$5.72M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.83M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CM
201
Caption Management
Oklahoma City,
Oklahoma
| – | -$167K | -12,000 | Closed |
|
202
Amundi
Paris,
France
| – | -$152K | -10,994 | Closed |
|
|
6M
203
6 Meridian
Wichita,
Kansas
| – | -$150K | -10,882 | Closed |
|
204
HSBC Holdings
London,
United Kingdom
| – | -$147K | -10,556 | Closed |
|
|
PAM
205
Panagora Asset Management
Boston,
Massachusetts
| – | -$2K | -110 | Closed |
|
206
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$1K | -53 | Closed |
|
|
QCG
207
Quadrant Capital Group
Cincinnati,
Ohio
| – | +$147 | +10 | +56% |
|
CHRS Hedge Fund Activity: Q3 2021 in Review
187 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2021, worth a combined $1.22B — up 14% from $1.08B a quarter earlier.
Fund positioning in CHRS was balanced in Q3 2021: 21 funds opened new positions, 21 closed out, 54 added to existing stakes and 78 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $15.8M. The largest seller was State Street, cutting an estimated $15.3M.
- 187 institutional investors held Coherus Oncology (CHRS) as of Q3 2021, down from 188 in Q2 2021.
- Funds reported $1.22B of Coherus Oncology stock for Q3 2021, up 14% quarter-over-quarter.
- 21 funds opened new Coherus Oncology positions in Q3 2021 and 21 closed out, a net change of 0 holders.
- The largest Coherus Oncology buyer in Q3 2021 was JP Morgan Chase, an estimated $15.8M added.
- The largest Coherus Oncology seller in Q3 2021 was State Street, an estimated $15.3M sold.
Based on aggregated 13F filings for Q3 2021.